As healthcare professionals, it is imperative to stay informed about diseases that significantly impact our patients' lives, such as Parkinson's Disease (PD). This neurodegenerative disorder affects millions globally and presents unique challenges due to its progressive nature and diverse symptomatology.
PD is characterized by the loss of dopaminergic neurons in the substantia nigra, leading to an imbalance in dopamine and acetylcholine. This imbalance results in motor and non-motor symptoms. The presence of Lewy bodies, protein aggregates mainly composed of alpha-synuclein, is another hallmark of PD.
PD typically manifests with motor symptoms such as tremors, bradykinesia, rigidity, and postural instability. However, non-motor symptoms like autonomic dysfunction, cognitive impairment, and mood disorders often precede motor symptoms and impact the quality of life significantly.
Diagnosis of PD is primarily clinical, based on history and physical examination. There are no definitive diagnostic tests, but neuroimaging can aid in differential diagnosis. Management involves pharmacological treatment, primarily levodopa, and non-pharmacological interventions like physiotherapy and occupational therapy.
Research is ongoing to understand the genetic and environmental factors contributing to PD, and to develop disease-modifying therapies. Deep Brain Stimulation (DBS) and stem cell therapy are promising advancements in the field.
Understanding Parkinson's Disease is crucial for healthcare professionals to provide comprehensive care. Staying updated with the latest research and advancements can help improve the quality of life for our patients and pave the way for future breakthroughs in management strategies.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation